NCT00336063 2026-04-13
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center